SUPN in the 13F filings
Supernus Pharmaceuticals Inc · CUSIP 868459108
- Quarter end
- 31 Dec 2025
- the date the book describes
- Filed
- 27 Oct 2026
- latest of these filings; the earliest 10 Feb 2026
- Managers listing it
- 29
- at least, of 95 tracked, among listed positions
- Comparable managers
- 92
- filed both Q3 2025 and Q4 2025; 5 listed it in both
- Shares listed
- 10,223,778
- combined, among listed positions
- Reported value
- $508m
- combined, at the quarter end
Among the 92 comparable managers: 17 buyers (opened or added shares) and 14 sellers (trimmed or exited), at least, among listed positions. Their net change in shares was +698,534.
Managers listing SUPN in Q4 2025
29 of 29 holders
Largest increases and reductions, by shares
Increases
- Millennium Management LLCexisting position · 2,640,066 shares now+2,293,773
- Point72 Asset Management LPexisting position · 2,264,800 shares now+503,316
- ExodusPoint Capital Management LPnew position · 229,126 shares now+229,126
- Freestone Grove Partners LPnew position · 196,318 shares now+196,318
- Brevan Howard Capital Management LPexisting position · 113,194 shares now+101,747
Reductions
- Citadel Advisors LLCexisting position · 452,959 shares now-963,967
- D. E. Shaw & Co.existing position · 707,982 shares now-271,622
- Two Sigma Investments LPexisting position · 120,666 shares now-137,310
- Jane Street Group LLCexisting position · 36,482 shares now-94,165
- Man Group PLCexisting position · 31,097 shares now-63,984
New positions and exits
New (3)
Exited (2)
- Woodline Partners LPwas $60m
- Two Sigma Advisers LPwas $884k
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q2 2014 | 1 | $1.1m | n.a. | n.a. |
| Q1 2015 | 1 | $1.3m | n.a. | n.a. |
| Q2 2015 | 2 | $10m | n.a. | n.a. |
| Q3 2015 | 1 | $10m | n.a. | n.a. |
| Q4 2015 | 2 | $23m | n.a. | n.a. |
| Q1 2016 | 3 | $38m | n.a. | n.a. |
| Q2 2016 | 2 | $33m | n.a. | n.a. |
| Q3 2016 | 1 | $43m | n.a. | n.a. |
| Q4 2016 | 1 | $42m | n.a. | n.a. |
| Q1 2017 | 1 | $51m | n.a. | n.a. |
| Q2 2017 | 2 | $68m | n.a. | n.a. |
| Q3 2017 | 3 | $53m | n.a. | n.a. |
| Q4 2017 | 1 | $51m | n.a. | n.a. |
| Q1 2018 | 5 | $70m | n.a. | n.a. |
| Q2 2018 | 3 | $122m | n.a. | n.a. |
| Q3 2018 | 2 | $45m | n.a. | n.a. |
| Q4 2018 | 5 | $50m | n.a. | n.a. |
| Q1 2019 | 5 | $61m | n.a. | n.a. |
| Q2 2019 | 6 | $54m | n.a. | n.a. |
| Q3 2019 | 3 | $46m | n.a. | n.a. |
| Q4 2019 | 6 | $28m | n.a. | n.a. |
| Q1 2020 | 7 | $29m | n.a. | n.a. |
| Q2 2020 | 4 | $33m | n.a. | n.a. |
| Q3 2020 | 3 | $49m | n.a. | n.a. |
| Q4 2020 | 1 | $47m | n.a. | n.a. |
| Q1 2021 | 1 | $46m | n.a. | n.a. |
| Q2 2021 | 2 | $48m | n.a. | n.a. |
| Q3 2021 | 3 | $40m | n.a. | n.a. |
| Q4 2021 | 2 | $36m | n.a. | n.a. |
| Q1 2022 | 4 | $62m | n.a. | n.a. |
| Q2 2022 | 4 | $62m | n.a. | n.a. |
| Q3 2022 | 5 | $75m | n.a. | n.a. |
| Q4 2022 | 5 | $53m | n.a. | n.a. |
| Q1 2023 | 3 | $55m | n.a. | n.a. |
| Q2 2023 | 2 | $45m | n.a. | n.a. |
| Q3 2023 | 1 | $40m | n.a. | n.a. |
| Q4 2023 | 1 | $40m | 0 | 1 |
| Q1 2024 | 3 | $91m | 2 | 1 |
| Q2 2024 | 1 | $45m | 1 | 2 |
| Q3 2024 | 3 | $61m | 3 | 0 |
| Q4 2024 | 3 | $75m | 2 | 1 |
| Q1 2025 | 3 | $54m | 1 | 2 |
| Q2 2025 | 3 | $80m | 3 | 0 |
| Q3 2025 | 6 | $244m | 5 | 1 |
| Q4 2025 | 9 | $381m | 17 | 14 |
| Q1 2026 | 8 | $399m | 17 | 15 |
| Q2 2026 | 6 | $299m | 15 | 16 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
SUPN and LLY →SUPN and JNJ →SUPN and VRTX →Choose a stock to compare with SUPN →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own SUPN, latest filings →Back to the 13F Explorer →